[ad_1]
Results from a Phase 3 clinical trial showed that median overall survival of nine months in patients with advanced bowel cancer was 5.4 months compared to 5.4 months. months for the current standard treatment.
The data suggested that encorafenib, binimetinib, and cetuximab, a combination of three drugs, should replace chemotherapy in patients with metastatic colorectal cancer and with a defect in the BRAF gene. Metastatic cancer can spread from one organ to another.
It is estimated that BRAF mutations occur in up to 15% of patients with metastatic colorectal cancer, V600E being the most common BRAF mutation and representing a poor prognosis for these patients.
"This study builds on a decade of research on the tumor biology of BRAF-mutated colorectal cancer and reflects a logical combination aimed at reducing the specific vulnerabilities of this tumor," said lead researcher Scott Kopetz, an badociate professor at BRAF. University of Texas, MD Anderson. Cancer Center in the United States.
"We are encouraged to see a significant improvement in the results with this new scheme for our patients," added Kopetz.
The international study was a multi-institutional collaboration with more than 200 centers around the world.
The clinical trial involved 665 patients with metastatic colorectal cancer with a BRAF mutation.
The findings were presented at the 2019 World Congress of the European Society of Medical Oncology (ESMO) on gastrointestinal cancer in Barcelona, Spain.
Posted: 7 July 2019 10:55
[ad_2]
Source link
